Search
for
Sort by
Research 31–60 of 289
- Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
- A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancer
- Antibody-drug conjugate induced hair loss responds to minoxidil: A case report
- Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
- Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
- Persistent Alopecia in a Breast Cancer Patient Following Taxane Chemotherapy and Adjuvant Endocrine Therapy: Case Report and Review of Post-treatment Hair Loss in Oncology Patients with Breast Cancer
- DRUG NEWS
- LBMON231 Virilization Secondary To Androgen Producing Ovarian Serous Cystadenoma
- Androgen receptor: A promising therapeutic target in breast cancer
- Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer
- Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review
- Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
- Evaluation of Androgen Receptor Expression and Its Association with Clinicopathological Features in Iraqi Women with Breast Cancer
- Neoadjuvant Therapy with Disitamab Vedotin in Treating Muscle-Invasive Bladder Cancer: A Case Report
- Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
- Permanent chemotherapy-induced alopecia: Case report and review of the literature
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- 202 Activation of breast cancer cell proliferation by ROR-alpha through aromatase promoter
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata
- Síndrome PRIDE: una práctica forma de identificar los efectos adversos cutáneos de los inhibidores del EGFR
- Aging and Immortality: Quasi-Programmed Senescence and Its Pharmacologic Inhibition
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Targeting the Wnt pathways for therapies
- Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies
- The Transcriptional Co-Activator cAMP Response Element-Binding Protein-Binding Protein Is Expressed in Prostate Cancer and Enhances Androgen- and Anti-Androgen-Induced Androgen Receptor Function
- Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Alopecia in patients treated with molecularly targeted anticancer therapies